Apparatus and method for cryogranulating a pharmaceutical composition
Cryogranulation systems with improved dispenser assemblies are provided for use in manufacturing frozen pellets of pharmaceutical substances in a fluid medium. Methods of cryogranulating the pharmaceutical substance in the fluid medium are also provided. In particular embodiments, the dispenser assembly is used with suspensions or slurries of pharmaceutical compositions including biodegradable substances, such as proteins, peptides, and nucleic acids. In certain embodiments, the pharmaceutical substance can be adsorbed to any pharmaceutically acceptable carrier particles suitable for making pharmaceutical powders. In one embodiment, the pharmaceutical carrier can be, for example, diketopiperazine-based microparticles. The dispenser assembly improves the physical characteristics of the cryopellets formed and minimizes product loss during processing.
1. A pharmaceutical dry powder comprising a diketopiperazine composition formed by the method of cryogranulating the diketopiperazine composition in suspension comprising the steps of dispensing a DKP composition in suspension through a dispenser assembly into a flow of a cooling agent to form the frozen pellets, the dispenser assembly including first and second rows of dispenser ports, the rows of dispenser ports being disposed perpendicularly with respect to the flow of the cooling agent, separating the frozen pellets from the cooling agent by a transport assembly, and transporting the frozen pellets to a pellet receptacle and lyophilizing frozen pellets.
2. The pharmaceutical dry powder of claim 1 wherein the pharmaceutical composition further comprises a pharmaceutically active ingredient or agent.
3. The pharmaceutical dry powder of claim 1 , wherein the substantially homogeneous frozen pellets range in diameter from 3-6 mm.
4. The pharmaceutical dry powder of claim 1 , wherein the diketopiperazine has the formula:
5. The pharmaceutical dry powder of claim 2 , wherein the pharmaceutically active agent comprises a peptide, protein or nucleic acid molecule.
6. The pharmaceutical dry powder of claim 2 , wherein the active agent is insulin.
7. The pharmaceutical dry powder of claim 2 , wherein the active agent is GLP-1.
8. The pharmaceutical dry powder of claim 2 , wherein the active agent is oxyntomodulin.
9. The pharmaceutical dry powder of claim 2 , wherein the active agent is parathyroid hormone or calcitonin.
10. The pharmaceutical dry powder of claim 1 , wherein 41% or more of the pellets have diameters greater than 4.75 mm.
11. The pharmaceutical dry powder of claim 1 , wherein 22% or less of the pellets have diameters less than 3.35 mm.
12. A pharmaceutical dry powder made by the method of forming a plurality of homogenous frozen pellets comprising diketopiperazine microparticles, the frozen pellets being formed by dispensing a pharmaceutical suspension through a dispenser assembly into a flow of a cooling agent to form the frozen pellets, the dispenser assembly including first and second rows of dispenser ports, the rows of dispenser ports being disposed perpendicularly with respect to the flow of the cooling agent, wherein the dispenser ports of the first and second rows are angled with respect to vertical and wherein the dispenser ports of the first row are disposed at opposite angles with respect to the dispenser ports of the second row, separating the frozen pellets from the cooling agent, and transporting the frozen pellets to a pellet receptacle and lyophilizing the frozen pellets.
13. The pharmaceutical dry powder of claim 12 , wherein the cooling agent is liquid nitrogen.
14. The pharmaceutical dry powder of claim 12 , wherein the pharmaceutical suspension comprises diketopiperazine-based microparticles in a fluid medium.
15. The pharmaceutical dry powder of claim 13 , wherein the pellets range in diameter from 3-6 mm.